Outstanding scientific achievement award lecture 2011: Defeating diabesity - The case for personalized combinatorial therapies

Diabetes

Volumn 61, Issue 6, 2012, Pages 1309-1314

  Tschöp, Matthias H ^a   DiMarchi, Richard D ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; AMYLIN; FIBROBLAST GROWTH FACTOR 21; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; LEPTIN; OXYNTOMODULIN; PEPTIDE YY [3-36]; RESISTIN; STEROID;

AWARDS AND PRIZES; BODY MASS; CALORIC RESTRICTION; CANCER RISK; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; DIABETIC OBESITY; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG POTENTIATION; DRUG SAFETY; GLUCOSE TOLERANCE; HUMAN; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RISK ASSESSMENT; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; WEIGHT GAIN; WEIGHT REDUCTION;

AWARDS AND PRIZES; DIABETES MELLITUS, TYPE 2; HUMANS; INDIVIDUALIZED MEDICINE; OBESITY; SOCIETIES, SCIENTIFIC;

EID: 84861890043     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0272     Document Type: Conference Paper

References (27)

1. Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005;352:1138-1145 (Pubitemid 40365358)
2. Makris A, Foster GD. Dietary approaches to the treatment of obesity. Psychiatr Clin North Am 2011;34:813-827
3. Aronne LJ, Powell AG, Apovian CM. Emerging pharmacotherapy for obesity. Expert Opin Emerg Drugs 2011;16:587-596
4. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432 (Pubitemid 24365442)
5. Greenwood HC, Bloom SR, Murphy KG. Peptides and their potential role in the treatment of diabetes and obesity. Rev Diabet Stud 2011;8:355-368
6. Hedbacker K, Birsoy K, Wysocki RW, et al. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab 2010;11:11-22
7. Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012;481:463-468
8. DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med 2007;356:2176-2183 (Pubitemid 47010843)
9. Bayham BE, Greenway FL, Bellanger DE, O'Neil CE. Early resolution of type 2 diabetes seen after Roux-en-Y gastric bypass and vertical sleeve gastrectomy. Diabetes Technol Ther 2012;14:30-34
10. Tam CS, Berthoud HR, Bueter M, et al. Could the mechanisms of bariatric surgery hold the key for novel therapies? Report from a Pennington Scientific Symposium. Obes Rev 2011;12:984-994
11. Stephens TW, Basinski M, Bristow PK, et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995;377:530-532
12. Nogueiras R, Tschöp MH, Zigman JM. Central nervous system regulation of energy metabolism: ghrelin versus leptin. Ann N Y Acad Sci 2008;1126:14-19 (Pubitemid 351589316)
13. Tschöp MH, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001;50:707-709 (Pubitemid 32242624)
14. Laferrère B, Reilly D, Arias S, et al. Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med 2011;3:80re2
15. Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 2008;105:7257-7262 (Pubitemid 351754465)
16. Müller TD, Sullivanc LM, Habegger K, et al. Restoration of leptin responsiveness in diet-induced obese mice by an optimized leptin analog in combination with exendin4 or FGF21. J Pept Sci. In press
17. Barrera JG, Sandoval DA, D'Alessio DA, Seeley RJ. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol 2011;7:507-516
18. Holloway SA, Stevenson JA. Effect of glucagon on oxygen consumption in the cold-adapted rat. Can J Physiol Pharmacol 1964;42:860-862
19. Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 coagonist eliminates obesity in rodents. Nat Chem Biol 2009;5:749-757
20. Pocai A, Carrington PE, Adams JR, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 2009;58:2258-2266
21. McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 2007;293:E1746-E1755 (Pubitemid 350255128)
22. Hansotia T, Maida A, Flock G, et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 2007;117:143-152 (Pubitemid 46048461)
23. Klein S, Jahoor F, Baba H, Townsend CM Jr, Shepherd M, Wolfe RR. In vivo assessment of the metabolic alterations in glucagonoma syndrome. Metabolism 1992;41:1171-1175
24. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301-304
25. Neel JV, Weder AB, Julius S. Type II diabetes, essential hypertension, and obesity as "syndromes of impaired genetic homeostasis": the "thrifty genotype" hypothesis enters the 21st century. Perspect Biol Med 1998;42:44-74
26. Speakman JR. Thrifty genes for obesity, an attractive but flawed idea, and an alternative perspective: the 'drifty gene' hypothesis. Int J Obes (Lond) 2008;32:1611-1617
27. Lunenfeld B, Sulimovici S, Rabau E. Mechanism of action of anti-ovulatory compounds. J Clin Endocrinol Metab 1963;23:391-394